Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 118,920 shares of CYTK, which is worth approximately $6.62 Million. The most recent transaction as insider was on Mar 05, 2024, when has been sold 32,604 shares (Common Stock) at a price of $67.54 per share, resulting in proceeds of $2,202,074. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 119K

10.59% 3M change

23.6% 12M change

Total Value Held $6.62 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 05 2024	SELL Open market or private sale	$2,202,074 $67.54 p/Share	32,604 Reduced 19.0%	138,973 Common Stock
Mar 05 2024	BUY Exercise of conversion of derivative security	$190,788 $6.67 p/Share	28,604 Added 14.58%	167,577 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$651,758 $67.68 p/Share	9,630 Reduced 6.74%	133,343 Common Stock
Feb 06 2024	SELL Open market or private sale	$2,585,250 $79.29 p/Share	32,605 Reduced 18.57%	142,973 Common Stock
Feb 06 2024	BUY Exercise of conversion of derivative security	$190,795 $6.67 p/Share	28,605 Added 14.01%	175,578 Common Stock
Jan 04 2024	SELL Open market or private sale	$1,363,829 $86.99 p/Share	15,678 Reduced 9.64%	146,973 Common Stock
Jan 04 2024	BUY Exercise of conversion of derivative security	$92,956 $7.96 p/Share	11,678 Added 6.7%	162,651 Common Stock
Nov 09 2023	SELL Open market or private sale	$88,500 $35.4 p/Share	2,500 Reduced 1.63%	150,664 Common Stock
Oct 12 2023	SELL Open market or private sale	$89,725 $35.89 p/Share	2,500 Reduced 1.61%	153,164 Common Stock
Sep 14 2023	SELL Open market or private sale	$87,150 $34.86 p/Share	2,500 Reduced 1.58%	155,664 Common Stock
Aug 10 2023	SELL Open market or private sale	$79,250 $31.7 p/Share	2,500 Reduced 1.56%	158,164 Common Stock
Jul 13 2023	SELL Open market or private sale	$88,425 $35.37 p/Share	2,500 Reduced 1.53%	160,664 Common Stock
Jun 08 2023	SELL Open market or private sale	$95,175 $38.07 p/Share	2,500 Reduced 1.51%	163,164 Common Stock
May 11 2023	SELL Open market or private sale	$70,586 $39.5 p/Share	1,787 Reduced 1.07%	165,396 Common Stock
May 03 2023	SELL Open market or private sale	$280,000 $40.0 p/Share	7,000 Reduced 4.02%	167,183 Common Stock
May 03 2023	BUY Exercise of conversion of derivative security	$55,720 $7.96 p/Share	7,000 Added 3.86%	174,183 Common Stock
Apr 13 2023	SELL Open market or private sale	$136,840 $34.21 p/Share	4,000 Reduced 2.34%	167,183 Common Stock
Mar 09 2023	SELL Open market or private sale	$156,400 $39.1 p/Share	4,000 Reduced 2.28%	171,183 Common Stock
Mar 06 2023	SELL Payment of exercise price or tax liability	$194,006 $39.13 p/Share	4,958 Reduced 3.54%	135,183 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	40,000 Added 18.59%	175,183 Common Stock
Mar 02 2023	SELL Payment of exercise price or tax liability	$427,086 $39.6 p/Share	10,785 Reduced 7.15%	140,141 Common Stock
Feb 16 2023	SELL Payment of exercise price or tax liability	$66,768 $44.13 p/Share	1,513 Reduced 0.99%	150,926 Common Stock
Feb 10 2023	SELL Bona fide gift	-	150 Reduced 0.1%	152,439 Common Stock
Feb 09 2023	SELL Open market or private sale	$174,920 $43.73 p/Share	4,000 Reduced 2.55%	152,589 Common Stock
Feb 09 2023	SELL Open market or private sale	$306,180 $43.74 p/Share	7,000 Reduced 4.28%	156,589 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM